Completed PHASE4 INTERVENTIONAL 2-arm NCT02533973

Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population

Sponsor: LEO Pharma

Interventions Daivonex® scalp solution Xamiol® gel

Updated 10 times since 2017 Last updated: Feb 21, 2025 Started: Sep 30, 2015 Primary completion: Mar 6, 2018 Completion: Mar 6, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02533973, this PHASE4 trial focuses on Psoriasis Vulgaris and remains completed. Sponsored by LEO Pharma, it has been updated 10 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Mar 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Mar 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2019 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 5 earlier versions

Dec 2018 — Jan 2019 [monthly]

Completed PHASE4
Jun 2018 — Dec 2018 [monthly]

Completed PHASE4
May 2018 — Jun 2018 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Sep 2017 — May 2018 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting
Jan 2017 — Sep 2017 [monthly]

Recruiting PHASE4

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

LEO Pharma
Tigermed Consulting Co., Ltd

Data source: LEO Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China